Stock Groups

U.S. CDC advisers to weigh limits on J&J vaccine due to blood clot issues

[ad_1]

© Reuters. FILE PHOTO: A vial and sryinge are seen in front of a displayed Johnson&Johnson logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration

WASHINGTON (Reuters) – Advisers to the U.S. Centers for Disease Control and Prevention will meet on Thursday to consider possible limits on the use of the Johnson & Johnson (NYSE:) COVID-19 vaccine because of blood clot issues, the Washington Post reported on Wednesday.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]